From the Guidelines

Aripiprazole and Chlorpromazine are not directly compared in the provided evidence.

The provided evidence discusses antipsychotic polypharmacy (APP) and its comparison to monotherapy, but does not specifically compare Aripiprazole and Chlorpromazine.
Aripiprazole is mentioned as a partial dopamine 2 agonist that can be combined with clozapine to reduce treatment side effects or residual symptoms 1.
However, Chlorpromazine is not mentioned in the provided evidence.

The evidence suggests that APP may be effective in reducing treatment side effects or residual symptoms in some patients, particularly when combining aripiprazole with clozapine 1.
A meta-analysis found that antipsychotic augmentation was superior to monotherapy regarding total symptom reduction, but this was only apparent in open-label low-quality trials 1.
Another meta-analysis did not find clear evidence to recommend the use of APP over monotherapy, but noted beneficial signals for some APP and augmentation strategies 1.

The evidence suggests that APP should be considered and discussed with patients who do not respond to monotherapy, but it is essential to weigh the potential benefits and risks of APP 1.
Clinicians should carefully evaluate the individual patient's needs and consider alternative treatment strategies before initiating APP 1.

From the Research

Aripiprazole and chlorpromazine are two different types of antipsychotic medications used to treat schizophrenia and other psychotic disorders 2, 3, 4.
Chlorpromazine is a typical antipsychotic, while aripiprazole is an atypical antipsychotic 2, 3.
Studies have compared the efficacy and tolerability of aripiprazole with other atypical antipsychotics, including olanzapine and risperidone 3, 5.
Aripiprazole has been shown to be less efficacious than olanzapine in terms of general mental state, but it is associated with fewer side effects such as cholesterol increase, weight gain, sedation, and prolactin-associated side effects 3.
Compared to risperidone, aripiprazole has been shown to have similar efficacy, but with a better tolerability profile in terms of dystonias, cholesterol increase, prolactin increase, and QTc prolongation 3, 5.
Chlorpromazine has been compared to atypical antipsychotics, including olanzapine, risperidone, and quetiapine, and has been shown to cause more extrapyramidal adverse effects 2.
There is limited direct comparison between aripiprazole and chlorpromazine, but a case report suggests that sudden withdrawal of chlorpromazine in patients treated with aripiprazole and chlorpromazine may lead to severe exacerbation of psychosis 6.

Aripiprazole has been shown to be effective in reducing psychotic symptoms and improving clinical response in patients with schizophrenia 3, 4.
Chlorpromazine has been shown to be effective in reducing psychotic symptoms, but it is associated with more extrapyramidal adverse effects compared to atypical antipsychotics 2.
Aripiprazole has a better tolerability profile compared to chlorpromazine, with fewer side effects such as weight gain, sedation, and prolactin-associated side effects 3, 4.

Clinicians should be aware of the potential risks and benefits of using aripiprazole and chlorpromazine in patients with schizophrenia and other psychotic disorders 2, 3, 4, 6.
The choice of antipsychotic medication should be individualized based on the patient's specific needs and medical history 3, 4.
Further studies are needed to directly compare the efficacy and tolerability of aripiprazole and chlorpromazine in patients with schizophrenia and other psychotic disorders 2, 3, 4.